Correspondence 0001683168-24-000852 from Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: Feb. 9, 2024 · CIK: 0001402328 · Accession: 0001683168-24-000852
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276817
Letter
RE: Sunshine Biopharma, Inc (CIK: 0001402328)
February 9, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement No. 333-276817 on Form S-1 (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp. hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:30 p.m. Eastern Time, on February 12, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution.
By: AEGIS CAPITAL CORP.
By: /s/ Robert Eide
Name: Robert Eide
Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
February 9, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Sunshine Biopharma, Inc (CIK: 0001402328)
Registration Statement No. 333-276817 on Form S-1 (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and
Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”),
Aegis Capital Corp. hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will
become effective at 4:30 p.m. Eastern Time, on February 12, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act,
please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable
to secure adequate distribution.
By:
AEGIS CAPITAL CORP.
By:
/s/ Robert Eide
Name: Robert Eide
Title: Chief Executive Officer